Strategic partnerships Fusion Antibodies collaborates with industry players like Finn Therapeutics and the National Cancer Institute, suggesting a strong openness to external collaborations that can lead to joint development programs and co-funded projects.

Early-stage focus The company emphasizes discovery and early development with proprietary platforms (CRX, RAMP, ADD), presenting a clear opportunity to offer high-value preclinical services, diagnostics, or tool licensing to accelerate client programs.

Clinical progression track With fifteen projects advancing to clinical stages and some reaching Phase II, there is demonstrated demand for outsourcing and specialized antibody development, indicating a potential for expanded CRO partnerships and late-preclinical services.

Financial growth signals Recent revenue updates and fundraising activity, including a £1.38m raise and revenue increases, imply growing client activity and budget availability for contract research, advisory, and platform licensing opportunities.

Global reach potential Publicly traded on LSE and headquarters in Belfast, combined with diverse tech stack and new collaboration announcements, point to readiness for scalable sales outreach to international pharmaceutical and biotech clients seeking trusted antibody discovery partners.